Answers are grounded in this paper and cite their sources.
Parkinson ’ s disease (PD) remains one of the most challenging areas in neurotherapeutics, with major progress in symptomatic treatment but persistent failure to deliver effective disease-modifying therapies. However, we are entering a new phase in therapeutic development for PD. Clinical trials are now targeting mechanisms closer to the presumed pathobiology of the disease, such as alpha-synuclein pathology or speci fi c genetic pathways. Furthermore, the imminent arrival of blood tests for diagnostic biomarkers will allow us to identify individuals at a much earlier disease phase when the underlying disease pathology is not yet far advanced, signi fi cantly expanding the pool of candidates for early interventions aimed at delaying disease progression
No takes yet. Share an insight, caveat, or question.
Outeiro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: